Analysts predict that Nabriva Therapeutics PLC – (NASDAQ:NBRV) will report earnings of ($0.47) per share for the current quarter, according to Zacks. Four analysts have made estimates for Nabriva Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.35). Nabriva Therapeutics reported earnings per share of ($0.54) in the same quarter last year, which would suggest a positive year over year growth rate of 13%. The company is scheduled to issue its next earnings report on Monday, August 6th.
According to Zacks, analysts expect that Nabriva Therapeutics will report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.36) to ($1.55). For the next fiscal year, analysts expect that the business will report earnings of ($1.77) per share, with EPS estimates ranging from ($2.41) to ($1.23). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Nabriva Therapeutics.
Nabriva Therapeutics (NASDAQ:NBRV) last released its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.36) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.23. Nabriva Therapeutics had a negative return on equity of 79.30% and a negative net margin of 600.34%. The business had revenue of $7.55 million for the quarter, compared to the consensus estimate of $1.27 million.
Several research firms have recently weighed in on NBRV. Northland Securities began coverage on Nabriva Therapeutics in a research note on Thursday, May 31st. They issued an “outperform” rating for the company. Cantor Fitzgerald set a $16.00 price target on Nabriva Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 30th. Bank of America boosted their price target on Nabriva Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, May 22nd. ValuEngine upgraded Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $18.00 price target on shares of Nabriva Therapeutics in a research note on Tuesday, May 8th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $16.81.
Shares of Nabriva Therapeutics traded down $0.02, hitting $3.48, during mid-day trading on Friday, Marketbeat reports. The company’s stock had a trading volume of 82,664 shares, compared to its average volume of 348,497. Nabriva Therapeutics has a 52-week low of $3.30 and a 52-week high of $14.10. The stock has a market capitalization of $140.78 million, a P/E ratio of -1.40 and a beta of 1.80.
In other news, General Counsel Robert Crotty acquired 10,000 shares of Nabriva Therapeutics stock in a transaction that occurred on Wednesday, May 23rd. The stock was bought at an average price of $4.48 per share, for a total transaction of $44,800.00. Following the completion of the transaction, the general counsel now owns 10,000 shares in the company, valued at $44,800. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen W. Webster acquired 8,000 shares of Nabriva Therapeutics stock in a transaction that occurred on Wednesday, May 23rd. The shares were purchased at an average price of $4.59 per share, with a total value of $36,720.00. Following the transaction, the director now owns 8,000 shares of the company’s stock, valued at approximately $36,720. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 32,660 shares of company stock valued at $139,711. 2.79% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of the stock. DRW Securities LLC purchased a new stake in Nabriva Therapeutics during the first quarter valued at $106,000. Dimensional Fund Advisors LP increased its position in Nabriva Therapeutics by 173.2% during the first quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock valued at $563,000 after acquiring an additional 70,917 shares during the last quarter. JPMorgan Chase & Co. increased its position in Nabriva Therapeutics by 163.9% during the first quarter. JPMorgan Chase & Co. now owns 24,959 shares of the biotechnology company’s stock valued at $126,000 after acquiring an additional 15,501 shares during the last quarter. BlackRock Inc. increased its position in Nabriva Therapeutics by 154.0% during the first quarter. BlackRock Inc. now owns 453,064 shares of the biotechnology company’s stock valued at $2,278,000 after acquiring an additional 274,709 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Nabriva Therapeutics during the first quarter valued at $244,000. Institutional investors own 62.16% of the company’s stock.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.